Clinical analysis of multiple small molecules dysregulating PI3K/AKT/mTOR pathway, including buparlisib (BKM120), pictilisib (GDC-0941), idelalisib, alpelisib (BYL719), serabelisib, taselisib (GDC-0032), gedatolisib (PF05212384), voxtalisib (SAR245409/XL765), MK2206, capivasertib (AZD5363), perifosine, uprosertib (GSK-2141795), aspirin, rapamycin, everolimus, temsirolimus, metformin, onatasertib (CC223), sapanisertib, and vistusertib (AZD2014) (204–207) (Figure 2) are found to reduce tumor progression and improve chemotherapy treatment efficacy (46, 47, 208–219). Here, PIK3CA is linked to neoplasm.